Krystal Biotech, Inc.

Biological Products, (No Diagnostic Substances)

KRYSStrained7 of 10 basics passed

$331.61

+1.32%

Market cap $9.82B

$331.61

+1.32%

Market cap $9.82B

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs.

It is a $9.82B healthcare company. Revenue grew 22.6% over the last year, it keeps 55¢ of every dollar of sales as profit, and it holds more cash than debt. It trades at 40.6× earnings — around the middle of its own history.

Website: krystalbio.com
Location: Pittsburgh, PA
Employees: 295
Sector: Healthcare

Share price · 3 years

$118.05 → $331.61+180.9%

price only — dividends excluded

Key facts · TTM

Revenue: total sales; $440M
Profit: keeps 55¢ of every $1 sold; $241M
Free cash flow: cash left after running the business; $258M
Net cash: more cash than debt; $818M
P/E: years of profit in the price; 40.6
EPS: earnings per share, TTM; $8.06
Shares: up 35% since 2021 — dilution; 30.0M
Volatility: beta vs the market — under 1 swings less; 0.64

Revenue, last 3 years

52-week range

Low $181.47$331.61High $378.15

Today's price is 76% of the way from the year's low to its high.

P/E vs its history3y

40.6×median 43.4×

Higher than 37% of past days — around the middle of its own history.

Valuation vs own history

P/E

40.6×

63%

P/S

22.3×

50%

EV/EBITDA

45.4×

85%

P/B

7.2×

FCF yield

2.6%

63%

Share of the last ~5 years that was pricier than today (in line with its own history). Based on the daily valuation record.

Insider activity · 90 days

-$932Knet selling

Purchases$0

Sales$932K

Insiders trading, last 14d0 buy · 0 sell

Standing in Healthcare

Size$9.82Btop 90%
Net margin55%top 1%
Return on equity19%top 34%
P/E40.6×top 80%

Ranked against 98 Healthcare companies with a full CV — for P/E, lower ranks higher.

Skills

Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.

Strong profitability; Valuation and Growth lag behind.

Valuation25

P/E vs own history37th pct · 20/25
FCF yield2.6% · 5/25
P/S22.3x · 0/25
EV/EBITDA46.1x · 0/25

Growth0

Revenue CAGRn/a · 0/25
Net income CAGRn/a · 0/25
EPS CAGR ~5Yn/a · 0/25
Fwd implied growth-0.3% · 0/25

Profitability95

ROIC51.1% · 25/25
ROE19.3% · 20/25
Net margin54.8% · 25/25
Operating margin44.9% · 25/25

Health50

Altman Zn/a · 0/25
Current ratio8.32 · 25/25
Interest coverage-52.5x · 0/25
Net cash / debtNet cash · 25/25

Quality60

Piotroski F5/9 · 15/25
Beneish M-2.36 · 20/25
FCF conversion107% · 25/25
Margin stabilityσ 371.0% · 0/25

Moat50

ROIC >12% years2/7 yrs · 0/25
Median gross margin93.9% · 25/25
FCF-positive years2/8 yrs · 0/25
Worst-year net marginworst 21.6% · 25/25

How the scores work →

Experience

The company's career so far — founding, the IPO, landmark products and acquisitions, plus revenue milestones and insider buying.

FY2025Financial
Best year on record
$205M net income
FY2023Financial
Turned profitable
$10.9M net income after a loss year

Achievements

Verifiable track record, straight from the reported numbers.

$10 000 invested in 2021 would be worth ~$58 911 today — price return only

$389.1M revenue in FY2025

Revenue up 22.6% year over year

Profitable 3 years in a row

295 employees

ROIC of 51.1%

Strengths & watch-outs

What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.

Strengths

High gross margin (94.6%)
Strongly profitable — 54.8% net margin
Revenue growing 22.6% year over year
Strong cash conversion — FCF is 58.5% of revenue
Net cash position after subtracting debt from cash

Watch-outs

Thin interest coverage (-52.5×)
Loss-making in 5 of the recent years

Qualifications

The basics a company should meet before you research it further. Each check uses the reported numbers.

7 of 10 checks passed

Revenue growing — the company sells more than a year ago+22.6% YoY
Profitable — makes more than it spends$241M TTM
Profit growing — earnings are higher than last year+129.7% YoY
Generates cash — cash left after running and investing$258M TTM
Debt under control — could handle its obligationsmore cash than debt
Established company — not a micro-cap — lower blow-up risk$9.82B market cap
Not printing shares — share count not ballooning — you keep your slice+34.9% shares over ~5y
Proven track record — years of profitability behind it3/8 profitable years
Financially stable — balance sheet not near distresshealth score 25/100
Pays a dividend — returns cash to shareholdersno data
Valuation not extreme — price not wildly above earningsP/E 40.6

Peer comparisonKrystal Biotech, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾

Company	Market cap	P/E	Revenue growth	Net margin	Profile
KRYS this company	$9.8B	40.6	+22.6%	54.8%	Strained
LLY Eli Lilly & Co.	$1.0T	41.6	+49.6%	33.5%	Solid
JNJ Johnson & Johnson	$630.9B	29.9	+8.1%	21.5%	Mixed
ABBV Abbvie Inc.	$488.5B	77.4	+10.4%	9.8%	Mixed
MRK Merck & Co., Inc.	$361.0B	113.2	+4.6%	4.8%	Mixed
UNH UNITEDHEALTH GROUP INCORPORATED (Delaware)	$340.7B	24.1	+6.5%	3.1%	Mixed
NVS Novartis AG	$273.2B	20.3	+9.6%	24.7%	Solid

Head-to-head: KRYS vs LLY · KRYS vs JNJ · KRYS vs ABBV

References

What covering analysts publish about the company — information only, not a recommendation.

Strong buy 7Buy 10Hold 2

Appendix · Financial records

The full statements behind this CV, FY2017–FY2025. For readers who want to check the numbers.

Profit & lossRevenue $440M · net income $241M (TTM)Open ▾

Profit & loss

Revenue and profit over the company's career — the income statement, visualised.

How FY2025 revenue flows to profit

RevenueNet income

Revenue (TTM)

$440M

YoY 22.6%

Net income (TTM)

$241M

Margin 54.8%

Gross margin

94.6%

Operating margin

44.9%

P/E ratio

40.6

Income statement — full detail

Figures in USD billions · EPS in USD

	2020	2021	2022	2023	2024	2025
Revenue	—	—	—	0.1	0.3	0.4
Gross profit	—	—	—	0.0	0.3	0.4
Operating income (EBIT)	-0.0	-0.1	-0.1	-0.1	0.1	0.2
Net income	-0.0	-0.1	-0.1	0.0	0.1	0.2
EPS (diluted)	—	-3.13	-5.43	0.39	3.00	6.84

Cash flowFree cash flow $258M · operating cash flow $272M (TTM)Open ▾

Cash flow statement

Cash generated by the business and what is left after investment — year by year.

Operating cash flowFree cash flow

Free cash flow (TTM)

$258M

Margin 58.5%

Operating cash flow (TTM)

$272M

FCF margin

58.5%

Cash flow statement — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Operating cash flow	-0.0	-0.0	-0.1	-0.1	0.1	0.2
Capital expenditure	-0.0	-0.1	-0.1	-0.0	-0.0	-0.0
Free cash flow	-0.0	-0.1	-0.2	-0.1	0.1	0.2
FCF margin	—	—	—	-198.4%	41.0%	48.5%

Balance sheetAssets $1.33B · net cash $818M (FY2025)Open ▾

Balance sheet

How the balance sheet is built — what it owns versus how it is financed.

How $1.33B of assets is financed

91%

Liabilities $114M — borrowed moneyEquity $1.22B — owners' stake

Cash vs debt

Total debt $9.34M − cash $828M = net cash $818M

Cash on hand covers all debt.

Debt repayment

Not needed

Cash already covers all debt

Interest coverage

-52.5x

EBIT ÷ interest expense

ROE

19.3%

Profit per $1 of equity

Balance sheet — full detail

Figures in USD billions

	2020	2021	2022	2023	2024	2025
Cash & equivalents	0.3	0.4	0.4	0.5	0.6	0.8
Total assets	0.3	0.6	0.6	0.8	1.1	1.3
Total liabilities	0.0	0.0	0.0	0.0	0.1	0.1
Total debt	—	0.0	0.0	0.0	0.0	0.0
Equity	0.3	0.6	0.5	0.8	0.9	1.2
Net debt	—	-0.4	-0.4	-0.5	-0.6	-0.8

Want the live picture — intraday moves, valuation history and full analysis?

Deeper analysis of KRYS on PreMarketPrice

Figures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $331.61 · market cap $9.82B.